These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35385681)

  • 1. Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective.
    Giacobbe DR; Roberts JA; Abdul-Aziz MH; de Montmollin E; Timsit JF; Bassetti M
    Expert Rev Anti Infect Ther; 2022 Jul; 20(7):963-979. PubMed ID: 35385681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives.
    Karvouniaris M; Pontikis K; Nitsotolis T; Poulakou G
    Expert Rev Anti Infect Ther; 2021 Jul; 19(7):825-844. PubMed ID: 33270485
    [No Abstract]   [Full Text] [Related]  

  • 3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    Scudeller L; Righi E; Chiamenti M; Bragantini D; Menchinelli G; Cattaneo P; Giske CG; Lodise T; Sanguinetti M; Piddock LJV; Franceschi F; Ellis S; Carrara E; Savoldi A; Tacconelli E
    Int J Antimicrob Agents; 2021 May; 57(5):106344. PubMed ID: 33857539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams.
    Gatti M; Pea F
    Expert Rev Anti Infect Ther; 2023 Feb; 21(2):149-166. PubMed ID: 36655779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
    Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
    Tamma PD; Hsu AJ
    J Pediatric Infect Dis Soc; 2019 Jul; 8(3):251-260. PubMed ID: 30793757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of carbapenem-resistant pathogens in cSSTI and how to manage them.
    Del Giacomo P; Losito AR; Tumbarello M
    Curr Opin Infect Dis; 2019 Apr; 32(2):113-122. PubMed ID: 30648994
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
    Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
    Clerici D; Oltolini C; Greco R; Ripa M; Giglio F; Mastaglio S; Lorentino F; Pavesi F; Farina F; Liberatore C; Castiglion B; Tassan Din C; Bernardi M; Corti C; Peccatori J; Scarpellini P; Ciceri F; Castagna A
    Int J Antimicrob Agents; 2021 Jun; 57(6):106335. PubMed ID: 33838223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Algorithm to Analyze Epidemiology and Outcomes of Carbapenem Resistance Among Patients With Hospital-Acquired and Ventilator-Associated Pneumonia: A Retrospective Cohort Study.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    Chest; 2019 Jun; 155(6):1119-1130. PubMed ID: 30685333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
    Sader HS; Castanheira M; Flamm RK; Mendes RE; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2015 Jul; 46(1):53-9. PubMed ID: 25956844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
    Lodise TP; Bassetti M; Ferrer R; Naas T; Niki Y; Paterson DL; Zeitlinger M; Echols R
    Expert Rev Anti Infect Ther; 2022 May; 20(5):707-719. PubMed ID: 34937518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of blaNDM-1 and blaVIM producing Gram-negative bacilli in ventilator-associated pneumonia at AMR Surveillance Regional Reference Laboratory in India.
    Kumari M; Verma S; Venkatesh V; Gupta P; Tripathi P; Agarwal A; Siddiqui SS; Arshad Z; Prakash V
    PLoS One; 2021; 16(9):e0256308. PubMed ID: 34495985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and
    Cruz-López F; Martínez-Meléndez A; Morfin-Otero R; Rodriguez-Noriega E; Maldonado-Garza HJ; Garza-González E
    Front Cell Infect Microbiol; 2022; 12():884365. PubMed ID: 35669117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany.
    Thelen P; Henriksen AS; Longshaw C; Yamano Y; Caldwell B; Hamprecht A
    J Glob Antimicrob Resist; 2022 Mar; 28():12-17. PubMed ID: 34920174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenem-Resistant
    Ramadan RA; Bedawy AM; Negm EM; Hassan TH; Ibrahim DA; ElSheikh SM; Amer RM
    Infect Drug Resist; 2022; 15():3537-3548. PubMed ID: 35833009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.